Keros Therapeutics, Inc. (KROS) Key Metrics
KROS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $211.4M
- Enterprise value
- −$11.3M
- P/E (TTM)
- —
- Forward P/E
- 48.8
- PEG ratio
- —
- Price / sales
- 14.1 10-yr median 67.9
- Price / book
- 0.9 10-yr median 3.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.12
KROS key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKROS valuation Price multiples at each fiscal year-end price.
KROS returns How much profit the business earns on the capital it uses.
KROS per-share figures Results divided by the shares outstanding at year-end.
KROS financial health Debt, liquidity and how easily interest is covered.
KROS efficiency & capital use Working capital cycle and where the cash goes.
KROS valuation history
KROS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KROS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KROS cash returned to shareholders
KROS price vs earnings per share
KROS key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $770.8M | $592.6M | $1.17B | $1.21B | $1.37B | $1.09B | — | — |
| Enterprise value | $500.3M | $51.6M | $854.1M | $946.3M | $1.14B | $828.8M | — | — |
| P/E ratio | 8.9 | — | — | — | — | — | — | — |
| Price / sales | 3.2 | 166.9 | — | 60.6 | 67.9 | 437.5 | — | — |
| Price / book | 2.5 | 1.0 | 3.5 | 4.4 | 5.6 | 4.2 | — | — |
| Price / free cash flow | 7.3 | — | — | — | — | — | — | — |
| Price / operating cash flow | 7.2 | — | — | — | — | — | — | — |
| EV / sales | 2.0 | 14.5 | — | 47.3 | 56.5 | 331.5 | — | — |
| EV / EBITDA | 5.4 | — | — | — | — | — | — | — |
| EV / free cash flow | 4.7 | — | — | — | — | — | — | — |
| Earnings yield | 11.3% | −31.6% | −13.1% | −8.6% | −4.3% | −4.1% | — | — |
| Free cash flow yield | 13.7% | −27.5% | −10.8% | −5.9% | −4.6% | −3.4% | — | — |
| Shareholder yield (dividends + buybacks) | 48.7% | 0.0% | — | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $20.36 | $15.83 | $39.76 | $48.02 | $58.51 | $70.54 | — | — |
| Per share | ||||||||
| Revenue per share | $6.45 | $0.09 | $0.01 | $0.79 | $0.86 | $0.16 | $1.13 | $1.13 |
| Earnings per share | $2.30 | −$5.00 | −$5.20 | −$4.15 | −$2.52 | −$2.93 | −$1.39 | −$0.15 |
| Operating cash flow per share | $2.84 | −$4.30 | −$4.23 | −$2.78 | −$2.66 | −$2.38 | −$1.80 | $0.79 |
| Free cash flow per share | $2.80 | −$4.35 | −$4.31 | −$2.82 | −$2.71 | −$2.40 | −$1.83 | $0.77 |
| Cash per share | $7.59 | $14.96 | $11.25 | $11.06 | $9.86 | $17.15 | $0.79 | $2.62 |
| Book value per share | $8.01 | $15.27 | $11.28 | $10.99 | $10.42 | $16.88 | $0.61 | $1.44 |
| Tangible book value per share | $8.01 | $15.27 | $11.28 | $10.99 | $10.42 | $16.88 | $0.61 | $1.44 |
| Capex per share | $0.04 | $0.05 | $0.08 | $0.05 | $0.04 | $0.02 | $0.03 | $0.02 |
| Debt per share | $0.45 | $0.50 | $0.49 | $0.53 | $0.05 | $0.06 | $0.60 | $0.29 |
| Shares outstanding | 37.9M | 37.4M | 29.4M | 25.2M | 23.3M | 15.5M | 8.9M | 8.9M |
| Change in shares outstanding | +1.1% | +27.1% | +16.7% | +8.2% | +50.5% | +74.6% | 0.0% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | 19.9% | −41.5% | −50.2% | −40.2% | −23.3% | −34.0% | −135.6% | −10.5% |
| Return on invested capital (ROIC) | 212.0% | −724.3% | −988.9% | −701.2% | −812.0% | — | — | — |
| Return on assets (ROA) | 18.2% | −38.0% | −45.2% | −37.3% | −22.4% | −32.4% | −64.3% | −4.9% |
| Return on tangible assets | 25.7% | −30.4% | −41.3% | −34.1% | −23.0% | −16.8% | −112.7% | −4.9% |
| Free cash flow margin | 43.4% | — | — | −356.5% | −314.3% | — | −162.7% | 68.2% |
| Income quality (OCF / net income) | 1.24 | — | — | — | — | — | — | — |
| Financial health | ||||||||
| Total debt | $16.9M | $18.9M | $14.4M | $13.3M | $1.1M | $899,000 | $5.3M | $2.6M |
| Cash & short-term investments | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M | $265.9M | $7.0M | $23.3M |
| Net debt | −$270.5M | −$541.1M | −$316.7M | −$265.8M | −$228.9M | −$265.0M | −$1.7M | −$20.7M |
| Debt / equity | 0.06 | 0.03 | 0.04 | 0.05 | 0.00 | 0.00 | 0.98 | 0.20 |
| Debt / assets | 0.05 | 0.03 | 0.04 | 0.04 | 0.00 | 0.00 | 0.49 | 0.09 |
| Net debt / EBITDA | −2.90 | — | — | — | — | — | — | — |
| Current ratio | 15.45 | 21.45 | 14.25 | 17.27 | 21.23 | 37.27 | 1.99 | 2.23 |
| Quick ratio | 15.45 | 21.45 | 13.67 | 17.32 | 20.97 | 37.06 | 1.82 | 2.23 |
| Interest coverage | — | — | — | — | — | — | — | -281.8 |
| Working capital | $295.0M | $561.4M | $322.9M | $269.2M | $239.6M | $260.5M | $4.4M | $14.1M |
| Invested capital | $32.6M | $30.5M | $15.5M | $11.6M | $14.2M | −$3.3M | $3.8M | −$7.9M |
| Tangible asset value | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M | $261.7M | $5.5M | $12.8M |
| Net current asset value | $280.5M | $544.6M | $309.5M | $256.4M | $239.4M | $260.0M | $3.4M | $10.9M |
| Graham number | $20.35 | — | — | — | — | — | — | — |
| Graham net-net per share | $6.80 | $13.86 | $10.23 | $9.90 | $9.99 | $16.71 | $0.29 | $0.97 |
| Capital allocation | ||||||||
| Share buybacks (net) | $375.0M | $0 | — | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | 353.9% | — | — | — | — | — | — | 0.0% |
| Capex / revenue | 0.6% | 54.4% | 1,631.8% | 6.2% | 5.1% | 11.8% | 2.7% | 2.2% |
| Capex / operating cash flow | 1.4% | — | — | — | — | — | — | 3.1% |
| Capex / depreciation | 1.03 | 1.57 | 3.02 | 1.84 | 2.71 | 1.06 | 0.62 | 1.42 |
| Stock-based compensation / revenue | 11.8% | 982.3% | 19,048.3% | 93.4% | 58.3% | 163.9% | 0.6% | 0.8% |
| R&D / revenue | 53.1% | 4,891.0% | 89,574.8% | 436.3% | 274.3% | 1,354.4% | 173.8% | 101.1% |
| SG&A / revenue | 19.2% | 1,148.0% | 23,068.9% | 137.6% | 106.1% | 511.9% | 31.8% | 15.8% |
| Efficiency | ||||||||
| Days sales outstanding | 8.1 | 285.2 | 2,335.0 | 173.7 | 167.2 | 83.1 | 33.7 | — |
| Days of inventory on hand | — | — | 2,958.7 | 250.5 | 921.0 | 673.6 | 16.0 | — |
| Days payables outstanding | 794.5 | 1,492.7 | 1,968.1 | 789.2 | 1,177.5 | 1,278.1 | 27.2 | 18.1 |
| Cash conversion cycle (days) | -786.4 | -1,207.5 | 3,325.7 | -365.0 | -89.3 | -521.4 | 22.4 | — |
| Receivables turnover | 45.08 | 1.28 | 0.16 | 2.10 | 2.18 | 4.39 | 10.85 | — |
| Payables turnover | 0.46 | 0.24 | 0.19 | 0.46 | 0.31 | 0.29 | 13.40 | 20.18 |
| Inventory turnover | — | — | 0.12 | — | 0.40 | 0.54 | 22.86 | — |
| Asset turnover | 0.51 | 0.01 | 0.00 | 0.07 | 0.08 | 0.02 | 0.52 | 0.36 |
| Average receivables | $5.4M | $2.8M | $966,000 | $9.5M | $9.2M | $569,000 | $922,000 | — |
| Average payables | $3.3M | $5.0M | $4.4M | $3.5M | $2.9M | $2.1M | $1.3M | $501,000 |
| Average inventory | — | — | $6.6M | $1.1M | $2.3M | $1.1M | $759,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from KROS's annual financial statements (latest annual report filed March 4, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KROS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Keros Therapeutics traded at 8.9 times earnings. Keros Therapeutics earned a return on equity of 19.9% and a return on invested capital of 212.0% in fiscal 2025. It ended the year with $16.9 million of debt and $287.4 million in cash and short-term investments, a net cash position of $270.5 million. It returned $375.0 million to shareholders: $0 in dividends and $375.0 million in share buybacks, 354% of free cash flow. The share count rose 326.2% from 8.9M to 37.9M over 7 years.
See the KROS income statement, the KROS chart for price history, or the KROS stock overview for the latest quote and news.
KROS key metrics FAQ
What is Keros Therapeutics's P/E ratio?
Keros Therapeutics traded at 8.9 times earnings at the end of fiscal 2025.
What is Keros Therapeutics's EV/EBITDA?
Keros Therapeutics's enterprise value was 5.4 times EBITDA at the end of fiscal 2025 (enterprise value $500.3 million, EBITDA $93.4 million).
What is Keros Therapeutics's return on equity?
Keros Therapeutics's return on equity (ROE) was 19.9% in fiscal 2025: net income of $87.0 million on average shareholders' equity of $437.3 million.
What is Keros Therapeutics's ROIC?
Keros Therapeutics's return on invested capital was 212.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Keros Therapeutics have?
Keros Therapeutics had total debt of $16.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.06 and more cash than debt.
Does Keros Therapeutics buy back its shares?
Yes. Keros Therapeutics spent $375.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +1.1% over the year, to 37.9M..
What is Keros Therapeutics's free cash flow yield?
Keros Therapeutics generated $106.0 million of free cash flow in fiscal 2025, a free cash flow yield of 13.7% on its market value at year-end ($770.8 million).
What is Keros Therapeutics's current ratio?
Keros Therapeutics's current ratio was 15.45 at the end of fiscal 2025: current assets were 15.45 times current liabilities.